Hanmi, Sanfer Partner to Bring GLP-1 Therapy to Mexico Hanmi Pharmaceutical has signed an exclusive distribution agreement with Mexico-based Laboratorios Sanfer to introduce efpeglenatide, a GLP-1 therapy for obesity, alongside Hanmis Dapalon Family diabetes treatments, marking a step in the South Korean companys global expansion strategy focused on metabolic diseases
Always return it to the refrigerator immediately after use
pg/mL, picograms per milliliter
Paired with a clean routine, hydrating molecules and barrier lipids, youre addressing the core biology of aging skin not just smoothing it for a night
but it must be expensive
The post suggests sharing the reason GLP-1 therapy is being considered, whether that is weight management, diabetes, or cardiovascular protection, along with the planned medication type, the infant age, and any maternal or infant medical concerns